Utilization, duration, and outcomes of neoadjuvant endocrine therapy in the United States
To evaluate if real-world utilization of neoadjuvant endocrine therapy (NET) is associated with similar rates of response and breast conservation surgery (BCS) compared to neoadjuvant chemotherapy (NAC).
Our population-based assessment used the National Cancer Data Base to identify women diagnosed with stage II–III, hormone receptor (HR)-positive BC who underwent surgery and received endocrine therapy from 2004 to 2014. Women were categorized by receipt of NET, NAC or no neoadjuvant therapy. We used logistic regression to assess differences in outcomes between therapies using inverse propensity score weighting to adjust for potential selection bias.
In our sample of 211,986 women, 6584 received NET, 52,310 received NAC, and 153,092 did not receive any neoadjuvant therapy. After adjusting for multiple relevant covariates and cofounders, there was no significant difference between NET and NAC with regard to BCS [odds ratio (OR) 0.91; 95% confidence interval (CI) (0.82–1.01)]; however, women who received NET were significantly less likely to achieve pCR [OR 0.34; 95% CI (0.23–0.51)] or a decrease in T stage [OR 0.39; CI (0.34–0.44)] compared to women treated with NAC. Patients who received NET for ≥ 3 months had higher odds of BCS (OR 1.59; 95% CI 1.46–1.73) and downstaging (OR 1.79; 95% CI 1.63–1.97) compared to patients who did not receive neoadjuvant therapy.
Women who received NET had similar rates of BCS compared to women who received NAC. Those who received NET for longer treatment durations had increased odds of BCS and downstaging compared to women who did not receive neoadjuvant therapy.
KeywordsNeoadjuvant endocrine therapy Neoadjuvant chemotherapy Breast conservation therapy Hormone positive breast cancer
Compliance with ethical standards
Pamela R. Soulos: 21st Century Oncology
Dr. Killelea: Advisory Board Member (2017), Genentech 2017 Advisory Board
Dr. Gross: Research Grants from Pfizer (PI) and Johnson & Johnson (Co-PI), as well as Genentech
Dr. Mougalian: Consulting (Eisai, Puma Biotechnology, Celgene); Research Grants from Pfizer and Genentech
Dr. Pariser: No disclosures
Ms. Sedghi: No disclosures
Ms. Soulos: Research Funding from 21st Century Oncology
- 5.Ellis M (2011) Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype -ACOSOG Z1031. J Clin Oncol 29:2342CrossRefGoogle Scholar
- 7.Smith IEDM, Ebbs SR (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23:5108–5116CrossRefGoogle Scholar
- 27.Suman VJ, Ellis MJ, Ma CX (2015) The ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2− invasive breast cancer. Chin Clin Oncol 4:34Google Scholar